Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early optimization of ceftazidime dosing in critical care
2024-519783-41-00Phase 2Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Jul 2025
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceftazidime in sepsis and bacterial disease, sponsored by CHU Saint-Etienne. Planned start Jul 2025; status: authorised.
02
Drugs
ceftazidime
03
Conditions
sepsisbacterial disease
Beyond the preview
Go deeper on 2024-519783-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519783-41-00.